Machines Without Manuals

African health systems have received substantial diagnostic hardware investment over the past two decades — PCR machines, biosafety cabinets, sequencers — but the quality management systems required to generate reliable, accreditable results from that hardware were not built alongside it. Only 430 of a target 2,500 laboratories have implemented quality management systems meeting international standards. The result is a continent where physical equipment exists but cannot be trusted to produce results that translate into clinical decisions or epidemiological surveillance.

The distribution of accredited labs reveals the structural failure: 370 of Africa's 520 accredited laboratories are in South Africa alone, meaning the 54 remaining AU member states share 150 accredited facilities. When the first African case of SARS-CoV-2 was reported, only 2 of 55 countries had the diagnostic capacity to detect it independently. Guinea's 2014 Ebola outbreak was not identified for three months after onset — a direct consequence of absent laboratory confirmation capacity — allowing unchecked community transmission during the critical early window. Ethiopia illustrates the workforce dimension: it requires an estimated 4,209 pathologists to meet population needs and currently has 61.

The dominant response to African diagnostic gaps has been equipment donation and disease-specific vertical programmes — separate laboratory networks for HIV, TB, malaria, and polio, each with its own supply chain, quality standards, and reporting structure. This approach produced hardware without integration: labs may have multiple machines from different programmes that cannot share reagents, maintenance contracts, or quality audits. The SLIPTA (Stepwise Laboratory Improvement Process Towards Accreditation) framework exists and is used, but uptake has been slow because accreditation requires sustained management capacity that most facilities do not have. Specimen referral systems remain fragmented by disease programme rather than organized as national tiered networks, so samples that cannot be tested locally often have no clear referral pathway. Hardware donations continue without commensurate investment in the quality management, maintenance, and workforce training that would make the hardware functional.

The tiered laboratory network model — national reference labs, regional hubs, peripheral facilities, with defined specimen referral pathways between them — is understood and has been implemented partially in some countries. Scaling it requires a workforce development pipeline that produces laboratory quality managers, not just laboratory technicians. It also requires converting disease-specific vertical infrastructure into shared horizontal capacity, which is a coordination and political problem as much as a technical one. Standardized quality management toolkits adapted for low-resource settings, combined with regional peer-accreditation support, could reduce the time and cost of moving individual labs through SLIPTA steps.

A systems design team could map the tiered network architecture problem in a specific country context: what referral pathways exist, where they break, and what minimum structural changes would create a functional national network. A workforce modelling team could estimate the pathologist and lab quality manager deficit across the continent by country and project what training pipeline investment would close it at different time horizons. A process team could analyze the SLIPTA step distribution across African labs to identify which quality management steps are most commonly stalled and what interventions have moved labs past those steps.